Yaz and Yasmin, birth control pills manufactured by Bayer, have been under extreme scrutiny since 2009. After completing its review of recent studies comparing the risk of blood clots in women taking drospirenone-containing pills such as Yaz and Yasmin, the FDA is requiring that the warning labels on Yaz and its sister drugs be strengthened. Back in December of 2011, the FDA’s advisory panel was split when asked to vote whether or not to keep Yaz on the market. Only 15 of the 26 members on the panel voted for the drug and 21 members voted that the information about the risks on the Yaz label were inadequate.
This new labeling went into effect April 10, 2012 and includes data from multiple international studies spelling out the risks to women who choose this type of birth control.
The New Yaz Warning Label
Yaz is a drospirenone-containing formulation that was originally marketed as a new form of birth control that offered women significant freedom and added benefits such as relief from bloating and even clearer skin. However, even Bayer’s official pre-launch trials noted a higher risk for potentially deadly events.
Further studies have found that women taking Yaz and similar drugs are potentially 2-3 times more likely to suffer a thrombotic event including deadly pulmonary embolisms, painful and potentially lethal DVT, and more. This risk is highest within the first year of use, as the parents of 20-year old Cindy Rippe discovered when their daughter died from an embolism after just two months of being on Yaz.
The new warning labels mandated by the FDA include data from multiple national and international studies on drospirenone in various forms of birth control including Yaz. It also includes visual aids including multiple charts so patients can clearly see the risk factors plotted out in pictures rather than relying on confusing figures and technical terminology.
Statistically, between 3 and 9 out of every 10,000 women on Yaz or another drospirenone birth control will develop some form of a venous or thrombotic event. For every 10,000 women not taking any birth control, that number falls between 1 and 5.
Even those FDA advisory panel members who voted for the drug to stay on the market recommended stricter controls. In fact, Sean Hennessy of the University of Pennsylvania said that although he voted to allow Yaz to stay on the market, “[I]t was a difficult vote.” He added that “[T]he drug probably ought to be rarely used.”
Yaz & Yasmin Lawsuits
The Rippe family is just one of the thousands of families nationwide that have been affected by Yaz and Yasmin. At least 50 fatal events have been recorded in association with the drug in addition to thousands of non-fatal events.
Combined, these potentially deadly side effects have spawned thousands of Yaz lawsuits and over 10,000 plaintiffs are seeking financial restitution and penalties against Bayer.
If you or a loved one has taken Yaz or Yasmin in the past and experienced any sort of thrombotic event including increased clotting, DVT, or embolism, you may be entitled to collect compensation. In addition, if you have experienced the loss of a loved one because of a thrombotic event related to Yaz, you may be entitled to sue on their behalf. To learn more about these Yaz lawsuits and your rights as a patient, contact one of our Yaz lawyers by calling toll-free (866) 981-4800 or filling out the form to your right.